Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Invimestrocel
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Recipient : Athersys
Deal Size : $151.5 million
Deal Type : Agreement
Details : Under the terms of the MOU, Athersys grants global rights to Healios to develop and commercialize MultiStem (Invimestrocel) for the treatment of acute respiratory distress syndrome (ARDS).
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : Invimestrocel
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Recipient : Athersys
Deal Size : $151.5 million
Deal Type : Agreement
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MultiStem® cell therapy (invimestrocel) is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic fac...
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Healios reported that last patient in its Phase 2/3 TREASURE study, evaluating MultiStem, a patented regenerative medicine product for the treatment of ischemic stroke, completed the 365-day follow-up visit.
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs
Details : MultiStem® cell therapy (invimestrocel) is patented regenerative medicine product has shown ability to promote tissue repair and healing in a variety of ways, such as through production of therapeutic factors in response to signals of inflammation and t...
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment
Details : The TREASURE study is a placebo-controlled, double-blind, phase 2/3 trial designed to confirm the efficacy and safety of MultiStem (HLCM051) in treating patients with ischemic stroke.
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 08, 2021
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HLCM051
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Athersys
Deal Size : Undisclosed
Deal Type : Agreement
Athersys Announces Cooperation Agreement With HEALIOS K.K.
Details : This agreement will enable both Athersys and Healios to focus on advancing their late-stage programs for MultiStem, including preparing for top line results from Healios’ TREASURE trial for stroke and ONE-BRIDGE trial for ARDS, which is expected this y...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 16, 2021
Lead Product(s) : HLCM051
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Athersys
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : HLCM051
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The SSC candidate of Healios (HLCM051) is in an ischemic stroke pivotal phase 2/3 trial in Japan in which it offers the potential to provide effective treatment over a much longer treatment window.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 01, 2020
Lead Product(s) : HLCM051
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Multipotent Adult Progenitor Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Memorial Hermann Hospital | US Department of Defense
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Multipotent Adult Progenitor Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Memorial Hermann Hospital | US Department of Defense
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Multipotent Adult Progenitor Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 29, 2020
Lead Product(s) : Multipotent Adult Progenitor Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HLCM051
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Healios to Enroll COVID-19 Patients in Phase II Off-the-Shelf Cell Therapy Program for ARDS
Details : HEALIOS K.K continues to make enrolment progress in its ONE-BRIDGE study, a phase II clinical trial in Japan evaluating the safety and efficacy of HLCM051.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : HLCM051
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable